Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.
Nanoligent has raised €13M across 2 funding rounds from 6 investors, most recently a round in Oct 2025. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-10-10 | Other | €12M | Biotech IV fund,CDTI,Clave Capital,Inveready | View deal → |
| 2022-02-04 | Other | €1.0M | AVANTECA Partners,Italian Angels for Growth (IAG) | View deal → |
